Logo of The Journal of Bone & Joint Surgery (Br)
Quick search:        
          Advanced Search
Guest Access | Sign In
Journal of Bone and Joint Surgery - British Volume, Vol 86-B, Issue 5, 719-725.
doi: 10.1302/0301-620X.86B5.14242  
Copyright © 2004 by British Editorial Society of Bone and Joint Surgery
This Article
Right arrow Full Text (PDF)
Right arrow FrenchSpanishItalianRomanianPolishRussianCzech
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow My Folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matsumine, A.
Right arrow Articles by Uchida, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matsumine, A.
Right arrow Articles by Uchida, A.

Calcium hydroxyapatite ceramic implants in bone tumour surgery

A LONG-TERM FOLLOW-UP STUDY

A. Matsumine, MD, Assistant Professor1; A. Myoui, MD, Assistant Professor2; K. Kusuzaki, MD, Associate Professor1; N. Araki, MD, Chief of the Department3; M. Seto, MD, Assistant Professor1; H. Yoshikawa, MD, Professor2; and A. Uchida, MD, Professor1

1 Department of Orthopaedic Surgery, Mie University, School of Medicine, 2-174, Edobashi, Tsu-city, Mie 514-8507, Japan.
2 Department of Orthopaedic Surgery, Osaka University, Medical School, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
3 Department of Orthopaedic Surgery, Osaka Medical, Center for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi, Higashinariku, Osaka 537-0025, Japan.

Correspondence should be sent to Dr A. Matsumine.

We reviewed the results of 51 patients with benign bone tumours treated by curettage and implantation of calcium hydroxyapatite ceramic (CHA). The mean follow-up was 11.4 years (10 to 15.5). Post-operative fractures occurred in two patients and three had local recurrences; three had slightly limited movement of the adjacent joint and one had mild osteoarthritis. There were no allergic or neoplastic complications. In all cases, radiographs showed that the CHA was well incorporated into the host bone.

Statistical analysis showed that absorption of the implanted CHA was greater in males (odds ratio, 6.2; 95% CI, 1.6 to 23.7) and younger patients (odds ratio, 0.6 for increase in age of 10 years; 95% CI, 0.91 to 0.99). However, the implanted CHA was not completely absorbed in any patient.

We conclude that CHA is a useful and safe bone substitute for the treatment of benign bone tumours.






(c) British Editorial Society of Bone and Joint Surgery All Rights Reserved
Registered charity no: 209299     Print ISSN: 0301-620X
Hip, Knee, Trauma, Upper limb, Foot & Ankle, Paediatrics, Oncology, Spine, Arthroplasty, General